Microviable Therapeutics, a Gijòn, Asturias, Spain-based preclinical stage biotechnology company, raised €1.5M in Seed funding.
Inmunomet Intolerancia y Disbiosis SL facilitated the round.
Microviable Therapeutics, founded in 2016 by Claudio Hidalgo Cantabrana (CEO), is a company that focuses on therapeutic products and technologies derived from the microbiota. In the past years, Microviable Therapeutics has developed a product to help with microbiota sampling. It now has clients in 15 countries. The company has also developed technology to store microbiota from humans for therapeutic purposes.
The company plans to use these funds to improve its therapeutic development platform and move its pipeline to the clinical phase. Pre-clinical results for MVT-201 are positive. This funding will allow the microbiota-derived product platform to be developed.